Region

Introducing

bioZen LC Columns

for Biologics Analysis

bioZen HPLC Information


  • Explore a New State of Zen for:
  • Peptide Mapping Aggregate Analysis Glycan Analysis Peptide Quantitation Drug Antibody Ratio Intact Mass Intact and Fragment Analysis
 
Ti Biocompatible Titanium Frit
 
Traditional Stainless Steel
 
Ti Biocompatible Titanium

Introducing bioZen HPLC/UHPLC Columns

With a new titanium hardware to minimize priming, two particle platforms for optimal versatility and seven particle chemistries to maximize selectivity and sensitivity, bioZen UHPLC/HPLC columns are seamlessly designed to bring peace of mind to your

  • Aggregate Analysis

    Quantitation of aggregate is a critical quality attribute in biopharmaceutical development. The determination of monomer, dimer, and multimer, as well as higher order structure (quaternary structural determination of a mAb), and high/low molecular weight species are commonly observed through size exclusion chromatography.

  • Drug Antibody Ratio (DAR)

    The average drug-to-antibody ratio (DAR) is critical to assess in the development of antibody-drug conjugates (ADCs). Though different chromatography modes can be employed to determine DAR, a highly effective method utilized reversed phase chromatography.

  • Glycan Analysis

    Glycosylation of proteins-specifically monoclonal antibodies-have indications on protein structure and is arguably the most critical post-translational modification to characterize in biopharmaceutical development. N-glycan analysis through hydrophilic interaction chromatography (HILIC) is a robust method for absolute quantitation of glycoforms and is the gold standard for glycosylation characterization.

  • Intact Mass

    Intact mass analysis involves using high resolution accurate mass (HRAM) instrumentation to confirm protein sequence and identify post-translational modifications. Often in combination with reversed phase chromatography, intact mass analysis is utilized on native proteins, mAbs, and ADCs in biopharmaceutical development.

  • Intact and Fragment Analysis

    Observation of intact protein and fragmented protein during impurity profiling is essential in biologic development. Utilizing reversed phase chromatography on native protein and partially fragmented protein scientists can observe characteristics including heavy chain/light chain, Fc/Fab, or isoforms.

  • Peptide Mapping

    For protein characterization, peptide mapping is commonly used for identification of non-enzymatic, spontaneous post translational modifications, such as deamidation, oxidation, succinimide formation, pyroglutamate formation, and others. Reversed phase chromatography is used for confirming primary sequence, but is more commonly for PTM identification.

  • Peptide Quantitation

    The determination of signature peptide concentration from biological matrices using LC-MS. Scientists utilize peptide quantitation to deconvolute complex chromatograms by searching for specific peptide sequences, which can analyze the peptides with high sensitivity and specificity, even at low levels of peptide.

  • Whether you are working with
  • or novel proteins,

    Complex large molecules composed of amino acid polymer chains. Proteins in biopharmaceuticals typically range from 3,000-150,000 kDa. Under the biologics classification, biopharmaceutical proteins can be hormones, human growth factors, and monoclonal antibodies (mAbs). The most common biopharmaceutical proteins are insulin and mAbs.

  • or biosimilars,

    A biologic with the same sequence and similar function to an innovator biologic. The characterization of biosimilars requires the same chromatographic techniques as its corresponding innovator biologic

  • bioZen UHPLC columns are guaranteed
  • to help you achieve a new
  • state of Zen for your mind, body, soul, and lab.
 

Zen for the Mind

Thoughtfully Designed Technologies

  • Thermally modified fully porous and core-shell technology particles offer unparalleled stability, robustness, and efficiency
  • Simplified selection for intact, peptide, glycan, and size exclusion methodologies
Learn More »
bioZen Thermally modified fully porous

Thermally modified fully porous

bioZen Core-shell Technology Particle

Core-shell Technology Particle

Zen for the Body

Separate a Large Body of Compounds

  • Specialized phases provide optimized elution windows for glycans, ADCs, and digested mAbs
  • bioZen columns offer better peak capacities and sharper peak shapes for increased sensitivity
Learn More »

Kadcyla (4 Signature Peptides)

Kadcyla - 4 Signature Peptides analyzed on bioZen UHPLC/HPLC columns

Zen for the Soul

Versatility Down to the Very Core

  • Biocompatible titanium hardware offers better recovery and reproducibility across all workflows
  • Enhanced protein characterization using RP-MS, SEC, High-Throughput-SEC, RP-UV, HILIC-FL, HILIC-MS
Learn More »
bioZen Titanium  UHPLC/HPLC columns

Zen for the Lab

Complete Support For All Your Methods

  • Full team of bioseparations Zen Masters to help you with your analysis
  • bioZen HPLC/UHPLC columns QC tested to ensure performance and reproducibility
Learn More »
bioZen Zen Masters Team Pics

Find Your Zen

Screening/Early Development mAb » Preclinical »

Example of bioZen at Work:

Adalimumab using bioZen 1.8 μm SEC-3

Trastuzumab using bioZen 1.8 μm SEC-3

Rituximab using bioZen 1.8 μm SEC-3

Herceptin - mcMMAF using bioZen 1.8 μm SEC-3

Excellent ADC Peak Shape!

Intact XB-C8


Intact XB-C8 Phase Information


Large pore core-shell particle for fast intact biologic entry. C8 provides highly useful moderate hydrophobic selectivity.

Phase: Particle Size: Pore Size: Length: Internal Diameter:
Loading...

Part Number:00B-4766-AN

Description:bioZen™ 3.6 µm Intact XB-C8, LC Column 50 x 2.1 mm, Ea

Required Holder:

Stationary Phase:

Solid Support:

Format:Column

Separation Mode:

Recommended Use:

USP Designation:


 Search Results


Part
Number
Brand Phase Particle
Size (µm)
Pore
Size (Å)
Length (mm) Internal
Diameter (mm)
Price